Ensysce Biosciences, Inc.
ENSC
Rank in Stocks
#29652
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to... Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Share Price
$0.3872
Last synced: 2026-11-12
Market Cap
$7.04M
Change (1 day)
7.53%
Change (1 year)
-81.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Ensysce Biosciences, Inc. (ENSC)
Category
Healthcare
Operating Margin for Ensysce Biosciences, Inc. (ENSC)
Operating Margin as of November 2026 TTM: -1,087.47%
According to Ensysce Biosciences, Inc.'s latest financial reports, its current operating margin (TTM) is -1,087.47%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Ensysce Biosciences, Inc. from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1,087.47% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -129.17% | -73.11% |
| 2023 | -480.41% | -49.95% |
| 2022 | -959.91% | 70.59% |
| 2021 | -562.71% | 1,271.13% |
| 2020 | -41.04% | -91.55% |
| 2019 | -485.74% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| -181.36% | -99.83% |
US
|
|
| 38.59% | -100.04% |
US
|
|
| -149.01% | -99.86% |
US
|
|
| 25.57% | -100.02% |
AU
|
|
| 31.23% | -100.03% |
BE
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Ensysce Biosciences, Inc.'s operating margin
What is Ensysce Biosciences, Inc.'s operating margin?
Ensysce Biosciences, Inc.'s operating margin is -1,087.47%, as of Nov 2026.
What was Ensysce Biosciences, Inc.'s operating margin in 2025?
In 2025, Ensysce Biosciences, Inc.'s operating margin was 0.00%, compared with -129.17% in 2024.
How has Ensysce Biosciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Ensysce Biosciences, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2022 (-959.91%).
How does Ensysce Biosciences, Inc.'s operating margin compare with similar companies?
Ensysce Biosciences, Inc.'s operating margin (-1,087.47%) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.